NASDAQ Market News 
HTG Molecular Appoints Dr. Joseph Sparano as Lead of Its Clinical Scientific Advisory Board for Breast Cancer Program
TUCSON, Ariz., Jan. 23, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) ...
Biocartis Group NV: BIOCARTIS SUCCESSFULLY RAISES EUR 55.50 MILLION
PRESS RELEASE: REGULATED INFORMATION - INSIDE INFORMATION23 January 2019, 21:30 CETBIOCARTIS SUCCESSFULLY RAISES ...
Biocartis Group NV: BIOCARTIS UPSIZES ITS EQUITY PLACEMENT DUE TO SIGNIFICANT DEMAND
PRESS RELEASE: REGULATED INFORMATION - INSIDE INFORMATION23 January 2019, 17:15 CETBIOCARTIS UPSIZES ...
$1.5 Billion Capnography Devices Market – Global Market Size, Share, Development, Growth and Demand Forecast, 2014-2025
Dublin, Jan. 23, 2019 (GLOBE NEWSWIRE) -- The "Capnography Devices Market by Component - ...
World-Renowned Oncologist Bullish on Potential of PharmaCyte’s Technology, Clinical Trial in Pancreatic Cancer
“I am excited about this new approach that has the potential to change the ...
Rexahn Announces Pricing of Public Offering of Common Stock and Warrants
ROCKVILLE, Md., Jan. 23, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) ...
Generex Announces REVISED Record Date for NuGenerex Immuno-Oncology Stock Dividend
MIRAMAR, FL , Jan. 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex Biotechnology ...
Long-term survival analysis of the randomised Phase III study shows a clear clinical benefit of inolimomab in SR-aGvHD
Long-term survival analysis of the randomised Phase III study shows a clear clinical benefit ...
Long-term survival analysis of the randomised Phase III study shows a clear clinical benefit of inolimomab in SR-aGvHD
Long-term survival analysis of the randomised Phase III study shows a clear clinical benefit ...
Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction in Pain
Bermekimab Treats HS Patients Even After Failure with Leading Biological TherapyAUSTIN, Texas, Jan. 23, ...
Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction in Pain
Bermekimab Treats HS Patients Even After Failure with Leading Biological TherapyAUSTIN, Texas, Jan. 23, ...
Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction in Pain
Bermekimab Treats HS Patients Even After Failure with Leading Biological TherapyAUSTIN, Texas, Jan. 23, ...
Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction in Pain
Bermekimab Treats HS Patients Even After Failure with Leading Biological TherapyAUSTIN, Texas, Jan. 23, ...